share_log

復星醫藥：海外監管公告 - 關於控股子公司獲藥品註冊批准的公告

FOSUN PHARMA: Overseas Regulatory Announcement - Announcement in Relation to the Approval for Drug Registration of a Subsidiary

HKEX ·  Oct 30 18:31

Summary by Moomoo AI

上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）宣布其控股子公司重慶藥友製藥有限責任公司開發的新藥「注射用鹽酸羅沙替丁醋酸酯」已於近日獲得國家藥品監督管理局的上市註冊批准。該新藥主要用於治療上消化道出血低危患者，並由重慶藥友製藥負責生產。截至2024年9月，復星醫藥集團對該新藥的研發投入約為人民幣331萬元。根據IQVIA CHPA的數據，2023年該類藥品在中國內地的銷售額約為人民幣9.43億元。復星醫藥預計此次新藥上市將為上消化道出血患者提供更多選擇，豐富產品線，但不會對集團當前業績產生重大影響。公司提醒投資者注意相關投資風險。
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）宣布其控股子公司重慶藥友製藥有限責任公司開發的新藥「注射用鹽酸羅沙替丁醋酸酯」已於近日獲得國家藥品監督管理局的上市註冊批准。該新藥主要用於治療上消化道出血低危患者，並由重慶藥友製藥負責生產。截至2024年9月，復星醫藥集團對該新藥的研發投入約為人民幣331萬元。根據IQVIA CHPA的數據，2023年該類藥品在中國內地的銷售額約為人民幣9.43億元。復星醫藥預計此次新藥上市將為上消化道出血患者提供更多選擇，豐富產品線，但不會對集團當前業績產生重大影響。公司提醒投資者注意相關投資風險。
Shanghai Fosun Pharma Group Co., Ltd. (referred to as "Fosun Pharma") announced that its holding subsidiary Chongqing Yaoyou Pharmaceutical Co., Ltd. has developed a new drug, "Rosaterol Hydrochloride Acetate for Injection", which has recently obtained registration approval for market launch from the National Medical Products Administration. The new drug is mainly used to treat low-risk patients with upper gastrointestinal bleeding and is produced by Chongqing Yaoyou Pharmaceutical. As of September 2024, Fosun Pharma Group has invested approximately 3.31 million RMB in the research and development of the new drug. According to IQVIA CHPA data, the sales of similar drugs in mainland China in 2023 were about 0.943 billion RMB. Fosun Pharma expects the launch of this new drug to provide more options for patients with upper gastrointestinal bleeding, enrich its product line, but will not have a significant impact on the group's current performance. The company reminds investors to pay attention to the related investment risks.
Shanghai Fosun Pharma Group Co., Ltd. (referred to as "Fosun Pharma") announced that its holding subsidiary Chongqing Yaoyou Pharmaceutical Co., Ltd. has developed a new drug, "Rosaterol Hydrochloride Acetate for Injection", which has recently obtained registration approval for market launch from the National Medical Products Administration. The new drug is mainly used to treat low-risk patients with upper gastrointestinal bleeding and is produced by Chongqing Yaoyou Pharmaceutical. As of September 2024, Fosun Pharma Group has invested approximately 3.31 million RMB in the research and development of the new drug. According to IQVIA CHPA data, the sales of similar drugs in mainland China in 2023 were about 0.943 billion RMB. Fosun Pharma expects the launch of this new drug to provide more options for patients with upper gastrointestinal bleeding, enrich its product line, but will not have a significant impact on the group's current performance. The company reminds investors to pay attention to the related investment risks.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated